Paul D Carter

US Patent:

6407213, Jun 18, 2002

Filed:

Nov 17, 1993

Appl. No.:

08/146206

Inventors:

Paul J. Carter - San Francisco CA
Leonard G. Presta - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 1600

US Classification:

5303873, 435 696, 435 697, 435 7021, 435 91, 536 2353, 4241331

Abstract:

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

US Patent:

6639055, Oct 28, 2003

Filed:

Nov 2, 2000

Appl. No.:

09/705686

Inventors:

Paul J. Carter - San Francisco CA
Leonard G. Presta - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 1600

US Classification:

5303873, 5303871, 5303881, 4241301

Abstract:

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

US Patent:

6719971, Apr 13, 2004

Filed:

Nov 2, 2000

Appl. No.:

09/705392

Inventors:

Paul J. Carter - San Francisco CA
Leonard G. Presta - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39395

US Classification:

4241301, 4241331, 4241361, 4241551, 4241411, 5303871, 5303881, 5303888, 53038885, 435 71

Abstract:

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

US Patent:

6800738, Oct 5, 2004

Filed:

Nov 2, 2000

Appl. No.:

09/705398

Inventors:

Paul J. Carter - San Francisco CA
Leonard G. Presta - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12P 2108

US Classification:

5303873, 5303871, 5303877, 53038815, 53038822, 5303888, 5303911, 5303897, 5303913, 5303915, 5303917, 4241301, 4241331, 4241341, 4241351, 4241361, 4241381, 4241411, 4241421, 4241431, 4241521, 4241551, 4241721, 4241741, 4241771

Abstract:

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

US Patent:

7018809, Mar 28, 2006

Filed:

Sep 18, 1992

Appl. No.:

08/199268

Inventors:

Paul J. Carter - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12P 21/06

US Classification:

435 691, 435 697, 435 701, 435 7021, 4351723, 435972, 5303891, 5303873

Abstract:

Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab′ and F(ab′)antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.

US Patent:

7288249, Oct 30, 2007

Filed:

May 28, 2003

Appl. No.:

10/447331

Inventors:

Paul J. Carter - San Francisco CA, US
John B. Ridgway - Pacifica CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241301, 4241381, 4241411, 4241551, 5303871, 5303877, 5302881, 5303888

Abstract:

The present application describes a method for making antibodies which can be used for cancer diagnosis or therapy. The application also discloses a method for identifying an antigen which is differentially expressed on the surface of two or more distinct cell populations. The application additionally describes human antibodies directed against decay accelerating factor (DAF), as well as therapeutic compositions comprising such antibodies. Moreover, the application discloses a method of treating lung cancer with antibodies directed against DAF.

US Patent:

7524937, Apr 28, 2009

Filed:

May 22, 2006

Appl. No.:

11/439325

Inventors:

Paul J. Carter - San Francisco CA, US
Nancy Y. Chiang - San Francisco CA, US
Kyung Jin Kim - Los Altos CA, US
William Matthews - Woodside CA, US
Maria L. Rodrigues - South San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 16/00

US Classification:

5303879, 5303881

Abstract:

Methods for identifying antibodies that decrease body weight, fat depot weight or food intake in an obese animal are provided, as well as antibodies. Preferred antibodies bind to a reactor having a WSX motif and the extracellular domain sequence within SEQ ID NO:2.

US Patent:

7642228, Jan 5, 2010

Filed:

Dec 7, 2001

Appl. No.:

10/010245

Inventors:

Paul J. Carter - San Francisco CA, US
Leonard G. Presta - San Francisco CA, US
John B. Ridgway - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39/395
A61K 38/16
C07K 14/00
C07K 16/00
C07K 16/46
C07K 19/00

US Classification:

514 2, 530300, 530350, 5303871, 5303873, 4241301, 4241331, 4241361, 4241781

Abstract:

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e. g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e. g.